top of page
LATEST NEWS
Orforglipron Weight-Loss Pill Trial Results: Eli Lilly Reports 12.4% Body Weight Reduction, Shares Fall 15%
Eli Lilly’s once-daily oral weight-loss pill, orforglipron, helped patients lose 12.4% of their body weight in a Phase 3 trial, but fell short of rival Wegovy’s results. The announcement sent Lilly shares down 15%, the company’s steepest drop in 25 years, despite meeting all primary and secondary endpoints and showing improvements in heart health markers.
Aug 11
Eli Lilly Acquires Verve Therapeutics for $1.3 Billion to Advance Gene Editing for Heart Disease
Eli Lilly has announced its $1.3 billion acquisition of Verve Therapeutics, a leading biotech company specializing in gene editing for cardiovascular diseases. This strategic move aims to accelerate the development of one-time gene therapies using base editing technology, targeting high-risk heart disease patients. The deal marks a significant step forward in Eli Lilly’s expansion into precision genetic medicine.
Jul 20
Capricor's Shares Drop After FDA Rejects Deramiocel Cell Therapy for Heart Disease in DMD
Capricor Therapeutics experienced a major setback after the FDA rejected its cell therapy, Deramiocel, for treating heart disease in Duchenne muscular dystrophy (DMD) patients. The decision led to a 30% drop in Capricor’s stock and highlighted the need for more efficacy data. Deramiocel, which uses cardiac-derived stem cells, aims to regenerate heart tissue and slow cardiomyopathy progression in DMD. Capricor plans to resubmit its application with additional clinical data lat
Jul 16
LEARN MORE
GENE TECH TIMES
The Future Has Arrived
Sarepta Pauses Elevidys Gene Therapy Trial After Second Death
Sarepta Therapeutics has paused its Duchenne muscular dystrophy (DMD) gene therapy, Elevidys, after a second patient death due to acute liver failure. The pause affects ongoing trials and therapy shipments, raising safety concerns—especially for non-ambulatory patients. Approved under the FDA’s accelerated pathway, Elevidys aimed to slow DMD progression, but recent events have sparked debate over gene therapy risks, regulatory oversight, and treatment decisions for affected f
Jul 1
Base Editor Gene Therapy for CPS1 Deficiency Treats Baby’s Rare Disorder
In a historic first, doctors used base editor gene therapy to treat a baby with CPS1 deficiency, a rare genetic liver disorder. The personalized treatment—delivered using lipid nanoparticles—led to improved ammonia levels and reduced medication needs. Unlike traditional CRISPR, base editing made precise DNA changes without cutting, offering a safer, more targeted option. This breakthrough marks a major step forward in treating rare diseases with gene-editing technology.
Jul 1
Enhance CAR T-Cell Therapy Efficacy and Reduce Toxicity by Using the Microbiome
Emerging research shows that the intestinal microbiome plays a vital role in the success of CAR T-cell therapy, influencing both efficacy and toxicity. Dr. Melody Smith’s studies reveal that certain antibiotics can disrupt the microbiome, reducing overall survival and increasing neurotoxicity risks. Optimizing gut health through diet or microbiome-targeted interventions may enhance CAR T-cell outcomes for cancer patients.
Feb 24
A Life Saved: Woman in Remission for 18 Years After Pioneering CAR T-Cell Therapy for Neuroblastoma
In an inspiring breakthrough for cancer treatment, a woman who underwent an experimental immunotherapy trial as a child has now been in...
Feb 18
Light-Induced Gene Therapy Using Nanoparticles Targets and Destroys Cancer Cells' Mitochondria
A groundbreaking new approach in cancer treatment has emerged, utilizing light to disable the mitochondria, the energy-producing...
Feb 9
bottom of page